[Development of an indicator set for the evaluation of the population-based integrated healthcare model 'Gesundes Kinzigtal' (Healthy Kinzigtal)].

Entwicklung eines Indikatorensets zur Evaluation der Integrierten Versorgung Gesundes Kinzigtal.
Indicator set Indikatorenset Integrated health care systems Integrierte Versorgung Quality Indicators Quality assessment Qualitätsbewertung Qualitätsindikatoren

Journal

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen
ISSN: 2212-0289
Titre abrégé: Z Evid Fortbild Qual Gesundhwes
Pays: Netherlands
ID NLM: 101477604

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 26 09 2019
revised: 03 04 2020
accepted: 03 04 2020
pubmed: 30 5 2020
medline: 25 9 2020
entrez: 30 5 2020
Statut: ppublish

Résumé

The project "INTEGRAL-10-year evaluation of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal)" (ICM-GK) is funded by the Innovation Committee of the Federal Joint Committee (G-BA) (grant no. 01VSF16002). The evaluation is to be based on a set of indicators that can be captured in routine data. On the one hand, they can be used to assess ICM-GK programs that are program-specific and geared towards prevention and disease management. On the other hand, possible negative side effects of the ICM-GK, which is designed as a "shared savings contract", are to be examined by also observing care needs not covered by the ICM-GK contract. Since an indicator set for the evaluation of regional integrated care (IC) programs in Germany is not yet available, a suitable indicator set should be developed. RESULTS: The methodological framework links the OECD concept for quality assessment of health systems with Kessner's tracer methodology. Disease groups with a high prevalence ("common diseases"), prevention potential and potential for improvement through IC were selected as tracers. The literature search resulted in 239 QIs and the QI database search in 293 QIs, which were supplemented by 21 QIs from the focus groups. Out of a total of 553 QIs, 251 QIs remained after removal of duplicates and comparison with the data basis. This preliminary QI set was reduced to 101 QIs by consensus. In addition, 48 health reporting indicators were supplemented which serve to classify regional quality results. The final QI set maps the following 19 disease categories/tracers: heart failure (16 QIs), myocardial infarction (4 QIs), CHD (10 QIs), stroke (6 QIs), metabolic syndrome (7 QIs of which 5 were diabetes-related), COPD (6 QIs), asthma (3 QIs), chronic pain (5 QIs), back pain (3 QIs), geriatrics (7 QIs), dementia (8 QIs), osteoporosis (3 QIs), rheumatism (3 QIs), multiple sclerosis (2 QIs), depression (4 QIs), antibiotic therapy (3 QIs), drug safety (1 QI), child care (5 QIs), early detection/prevention (5 QIs). 33 of these QIs are dedicated to five tracers that are not explicitly ICM-GK programs. Most QIs assess aspects of the effectiveness of care for the chronically ill and measure process quality. The set of indicators initially enables the quality assessment of regional, cross-indication care quality in the population-based integrated health care model 'Gesundes Kinzigtal' on the basis of routine data. Although the QI set focuses on effectiveness and process quality, it also includes QIs for preventive and acute care, coordination of care, patient orientation and safety, and outcomes. In contrast to other QI sets, both primary care and specialist health care and integrated, cross-sectoral and cross-professional care aspects have been considered. The benefits of the QI set for comparisons of regional quality and the evaluation of different IC programs remain to be tested. On the basis of a broadly based research and participatory development process, a set of indicators has been developed that enables comprehensive evaluation of the regional quality of care of cross-indication, integrated care models focusing on common diseases. In order to be able to increasingly evaluate aspects of care coordination and patient orientation, health promotion as well as nursing, palliative and emergency care in the future, it would be helpful if routine data were collected or made accessible in these areas as well.

Identifiants

pubmed: 32467041
pii: S1865-9217(20)30041-6
doi: 10.1016/j.zefq.2020.04.001
pii:
doi:

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

54-64

Informations de copyright

Copyright © 2020. Published by Elsevier GmbH.

Auteurs

Max Geraedts (M)

Fachbereich Medizin, Philipps-Universität Marburg, Marburg, Deutschland. Electronic address: geraedts@uni-marburg.de.

Claudia Mehl (C)

Fachbereich Medizin, Philipps-Universität Marburg, Marburg, Deutschland.

Jutta Schmitz (J)

Fachbereich Medizin, Philipps-Universität Marburg, Marburg, Deutschland.

Achim Siegel (A)

Universitätsklinikum Tübingen, Universität Tübingen, Tübingen, Deutschland.

Erika Graf (E)

Medizinische Fakultät, Universität Freiburg, Freiburg, Deutschland.

Dominikus Stelzer (D)

Medizinische Fakultät, Universität Freiburg, Freiburg, Deutschland.

Erik Farin-Glattacker (E)

Medizinische Fakultät, Universität Freiburg, Freiburg, Deutschland.

Peter Ihle (P)

PMV forschungsgruppe an der Medizinischen Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland.

Ingrid Köster (I)

PMV forschungsgruppe an der Medizinischen Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland.

Patrik Dröge (P)

Wissenschaftliches Institut der Ortskrankenkassen, Berlin, Deutschland.

Christian Günster (C)

Wissenschaftliches Institut der Ortskrankenkassen, Berlin, Deutschland.

Nathalie Haas (N)

Gesundes Kinzigtal GmbH, Hausach, Deutschland.

Oliver Gröne (O)

OptiMedis AG & London School of Hygiene and Tropical Medicine, London, Großbritannien.

Ingrid Schubert (I)

PMV forschungsgruppe an der Medizinischen Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH